PRESENTATION

Q3 2024 — Presentation

Q3 2024PDF · 29 pages1.7 MB
Merck
Q3 2024 Earnings
October 31, 2024

-- 1 of 29 --

Agenda
2
Strategy and
Business Update
Rob Davis
Chairman and Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 29 --

Forward-looking statement of Merck & Co., Inc.,
Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and
are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary
regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency
exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward
health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including
obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report
on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).

-- 3 of 29 --

Strategy and
Business Update
Rob Davis
Chairman and Chief Executive Officer

-- 4 of 29 --

Delivered on our key strategic priorities in Q3 2024
Advanced the pipeline to meet
patient unmet need
Achieved strong commercial and
financial performance
Executed on strategic business
development to augment pipeline
Created long-term value for patients
and shareholders
5

-- 5 of 29 --

20,000
30,000
40,000
50,000
60,000
70,000
2022 	2023 	2024
Strong Q3 underlying performance1
6
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Merck does not exclude charges for certain upfront payments and income from certain receipts related to
collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Third quarter of
2024 includes a net charge of $0.79 per share for such items. Full year non-GAAP outlook for 2024 and full year reported results for 2023 and 2022 include $1.05, $6.21 and $0.22 per share of
such net charges, respectively. 3. GAAP EPS $1.24.
$16.7B
+4%
+7% ex-Exchange
Q3 Worldwide Sales
Q3 Non-GAAP EPS3
$5.37
Full Year Sales
Full Year Non-GAAP EPS2
$59.3B
+22%
$60.1B
+1%
2022 	2023 	2024
$1.51
$7.48
GUIDANCE RANGE
$63.6B - $64.1B
+6% - +7%
GUIDANCE RANGE
$7.72 - $7.77
$1.57

-- 6 of 29 --

Advancing and broadening our diverse pipeline
7
Infectious Disease
Presented positive Phase 2
islatravir and lenacapavir
combination data for HIV
Vaccines
Presented positive Phase 2b/3
results for clesrovimab, & ACIP
voted to expand recommendation
for CAPVAXIVE to 50-64
Immunology
Presented positive Phase 2
maintenance data for tulisokibart
in UC and CD
Oncology
Presented data for 10
investigational or approved
medicines at ESMO
Business Development
Acquired CN201 (MK-1045) from
Curon with potential applications
in oncology and immunology

-- 7 of 29 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 8 of 29 --

Strong Q3 worldwide sales growth
9
Merck
WORLDWIDE SALES1
$16.7B+4% growth
+7% ex-exchange 2
$14.9B
+5% growth
+8% ex-exchange2
Human Health
$1.5B
+6% growth
+11% ex-exchange2
Animal Health
1. Worldwide Sales includes Other Revenue. 2. ~2 percentage points of the negative impact of foreign exchange for Worldwide Sales, Human Health and Animal Health,
was due to devaluation of the Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.

-- 9 of 29 --

Oncology: KEYTRUDA continues to drive exceptional growth
10	Growth rates exclude the impact of foreign exchange.
1. ~3 percentage point negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.
• KEYTRUDA sales of $7.4B increased 21%1
year-over-year, driven by uptake in earlier
stage cancers and continued robust global
demand from metastatic indications
– In the U.S., growth reflects increased use in
resectable NSCLC, as well as uptake from KN-A39
in advanced urothelial cancer
– Ex-U.S. growth reflects continued uptake in
earlier stage cancers, including high-risk, early-
stage TNBC, as well as demand from metastatic
indications
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
3Q22 	3Q23 	3Q24
$5.4B
+26%
$7.4B
+21%
$6.3B
+17%

-- 10 of 29 --

Oncology: Updates across broad portfolio
• Lynparza 1 sales grew 13%, driven primarily
by increased global demand
• Lenvima 2 sales declined 4%, driven primarily
by timing of shipments last year
• WELIREG sales more than doubled, driven
by increased uptake in certain patients with
previously treated advanced RCC
$181M
+15%
$151M
+57%
11	Growth rates exclude the impact of foreign exchange.
1. In collaboration with AstraZeneca 2. In collaboration with Eisai
3Q22 	3Q23 	3Q24
$299M
+6%
$284M
+23%
$337M
+13%
3Q22 	3Q23 	3Q24
$260M
+30%	$202M
+11%
$251M
-4%
3Q22 	3Q23 	3Q24
$54M
+43%$38M
$139M
+157%

-- 11 of 29 --

3Q22 	3Q23 	3Q24
$1.7B
+40%
3Q22 	3Q23 	3Q24
$2.6B
+16%
Vaccines: Broad vaccines portfolio having significant patient impact
12
• GARDASIL sales of $2.3B decreased 10%
year-over-year, driven by a decline in China
– In the U.S., sales benefitted from CDC
purchasing patterns, as well as price and
demand
– Ex-U.S. sales increased by double digits in
almost every region driven by robust demand
• VAXNEUVANCE sales of $239M grew 13%,
driven by ongoing launches in ex-U.S.
markets
• Recent launch of CAPVAXIVE off to an
encouraging start
Growth rates exclude the impact of foreign exchange.
$2.3B
-10%
$2.3B
+20%
$16M
$214M $239M
+13%

-- 12 of 29 --

Cardiovascular: Continued successful launch of WINREVAIR
13
$1.7B
+40%
$1.9B
+27%
$2.5B
+4%
Q3 sales of $149M
Payors
 
Prescribers
 
Patients
• 	Achieved coverage for ~60% of lives since launch
• 	Many payors established coverage policies consistent with the label or
STELLAR criteria
• 	~1,700 new patients prescribed in the quarter
• 	>3,700 total patients prescribed since launch
• 	~80% of prescribed patients receive commercial product
• 	>2,600 commercial patients started treatment since launch
• 	~10,000 total prescriptions written since launch
• 	Nearly 800 physicians have written at least one prescription since launch
• 	Most prescribers are from large academic centers or larger private practices
• 	Physicians continue to prioritize the sickest PAH patients
Positive initial feedback following recent EU approval

-- 13 of 29 --

Animal Health: Strong growth across companion animal and livestock
14
• Animal Health sales increased 11% 1 to $1.5B
– Companion Animal grew 17%, driven by uptake
from new product launches and price
– Livestock sales grew 7%, driven by higher
demand for poultry and swine products, the
inclusion of sales from the recently expanded
aqua portfolio, and price
3Q22 	3Q23 	3Q24
$1.4B
+4%
$1.4B
+2%
$1.5B
+11%
Growth rates exclude the impact of foreign exchange.
1. ~2 percentage point negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.

-- 14 of 29 --

Q3 2024 non-GAAP financial results summary1
Q3 2024 	Q3 2023 	Change Change
Ex-FX
Sales 	$16.7 	$16.0 	+4% 	+7%
Non-GAAP Gross Margin 	80.5% 	77.0% 	+3.5pts 	+3.4pts
Non-GAAP Operating
Expenses $8.5 	$5.8 	+48% 	+49%
Non-GAAP Tax Rate 	21.9% 	15.0% 	+6.9pts 	N/A
Non-GAAP EPS2,3 $1.57 	$2.13 	-26% 	-23%
$ in billions, except EPS amounts
15
1. Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying
business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP
results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other
metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should
be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached
to the earnings release. 2. Q3 2024 includes a net charge of $0.79 per share for the EyeBio (including milestone), Curon and Daiichi Sankyo transactions. 3. Q3 2024 GAAP EPS of $1.24

-- 15 of 29 --

Updated 2024 financial outlook
1. Guidance does not assume any additional significant potential business development transactions.
16
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue 	$63.4B to $64.4B 	$63.6B to $64.1B • 	Assumes ~3 percentage point FX headwind (no change)
• 	Implies growth of 6% to 7%
Non-GAAP
Gross Margin Rate ~81.0% 	~81.0%
Non-GAAP
Operating Expenses1 	$26.8B to $27.6B 	$27.8B to $28.3B • 	Now includes $750 million one-time charge related to the
asset acquisition from Curon
Other (Income) / Expense 	~$350M of expense 	~$100M of expense 	• 	Now includes $170 million payment from Daiichi Sankyo
Tax Rate 	~15.5% to 16.5% 	~16.0% to 17.0% • 	Now includes unfavorable impact related to the Curon
transaction
Shares Outstanding 	~2.54B 	~2.54B 	• 	Assumes modest share repurchase (no change)
Non-GAAP EPS 	$7.94 to $8.04 	$7.72 to $7.77
• 	Now includes one-time $0.29 charge related to the Curon
transaction, and $0.05 benefit related to payment from
Daiichi Sankyo
• 	Assumes ~$0.30 FX headwind in 2024 (no change)

-- 16 of 29 --

17
Continue to invest in the
pipeline and business while
augmenting the pipeline
with value-enhancing
business development
$3.1
$0.8
$2.0
$3.2
$0.4
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
Q3 Spend ($ in billions) 1
1. 	Reflects quarter spend
2. 	Reflects R&D excluding Business Development
Remain committed to balanced capital allocation strategy
Capital allocation order of priority
2

-- 17 of 29 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 18 of 29 --

Important updates across our vaccines, immunization
and infectious disease programs
19
RSV
• 	CDC’s ACIP voted in favor of
expanding the age-based
recommendation for
CAPVAXIVE to individuals
50-64 years of age
• 	Decision expands on initial
ACIP recommendation for
individuals age 65+
• 	Presented results at IDWeek
from Phase 2b/3 trial evaluating
clesrovimab, an investigational
RSV preventative monoclonal
antibody for infants entering
their first RSV season
• 	Clesrovimab significantly reduced
incidence of RSV through 5
months, the primary endpoint,
and hospitalizations associated
with RSV infection through 5
months, the secondary endpoint
• 	If approved, clesrovimab would
be the first and only
immunization designed to
provide infants with protection
for full 6-month RSV season
with convenience of one dose,
regardless of weight
Pneumococcal 	HIV
• 	Presented results at IDWeek
from Phase 2 trial evaluating
combination of islatravir and
lenacapavir1 as once-weekly oral
treatment option for people
living with HIV
• 	48-Week results build on positive
24-Week data previously
presented
1. In collaboration with Gilead

-- 19 of 29 --

Renal
Head & Neck
Skin
Extensive ongoing, Phase 3 clinical development program for
KEYTRUDA-based regimens in earlier stages of cancer1
20
FDA approved indications
Demonstrated OS benefit2
4
9 Breast
Gynecological
Liver
Lung
Bladder
KN-091
KN-671
KV-006
KN-937
LEAP-012
KN-564
LITESPARK-022
KN-057
KN-123
KN-689
KN-522
KN-756
KN-054
KN-716
KN-629
KN-A18
1. Operable and/or no/limited spread to other parts of the body
2. Achieved OS in cancer type (not all currently labeled)
3. INTerpath-007 in csCC Ph 2/3 development
Announced positive data for:
Esophageal
KN-975
KL-012
KL-013
TroFuse-019
INTerpath-002
INTerpath-009
KN-866
KN-676
KN-905
KN-992
KN-B15
INTerpath-001
INTerpath-007 3
KN-242
TroFuse-012
KN-689
KN-123
KN-756
LEAP-012

-- 20 of 29 --

Recent Approvals 	ESMO
21
Broadening the impact of KEYTRUDA
U.S.
 	• 	KEYNOTE-483: FDA approved KEYTRUDA in combination with pemetrexed and platinum
chemotherapy for 1L treatment of adult patients with unresectable advanced or metastatic
malignant pleural mesothelioma
Europe
• 	KEYNOTE-A39: EC approved KEYTRUDA in combination with Padcev for 1L treatment of adult
patients with unresectable or metastatic urothelial carcinoma
• 	KEYNOTE-868: EC approved KEYTRUDA in combination with carboplatin and paclitaxel for 1L
treatment of certain patients with primary advanced or recurrent endometrial carcinoma
• 	KEYNOTE-A18: EC approved KEYTRUDA in combination with chemoradiotherapy for
treatment of certain patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer
Japan
• 	KEYNOTE-052: MHLW approved KEYTRUDA for treatment of patients with radically
unresectable urothelial carcinoma not eligible for any platinum-containing chemotherapy
• 	KEYNOTE-671: MHLW approved KEYTRUDA for neoadjuvant and adjuvant treatment of
certain patients with resectable NSCLC
• 	KEYNOTE-A39: MHLW approved KEYTRUDA in combination with Padcev for 1L treatment of
patients with radically unresectable urothelial carcinoma
• 	Three presentations for KEYTRUDA
showcased during Presidential Symposium
sessions:
• 	OS data from KEYNOTE-522 in
patients with high-risk early-stage
triple-negative breast cancer
• 	OS data from KEYNOTE-A18 in
patients with newly diagnosed, high-
risk, locally advanced cervical cancer
• 	10-year follow-up OS data from
KEYNOTE-006 showing long-term
benefit over ipilimumab in patients with
advanced melanoma

-- 21 of 29 --

Continuing to advance our broader oncology program with BD
22
Exelixis 	Daiichi Sankyo
• 	Announced clinical development collaboration with
Exelixis to evaluate investigational tyrosine kinase
inhibitor, zanzalintinib in combination with:
• 	KEYTRUDA for treatment of patients with HNSCC
• 	WELIREG for treatment of patients with RCC
• 	Initiated Phase 3 IDeate-Lung02 trial evaluating I-DXd,
a B7-H3 directed antibody drug conjugate, for
treatment of patients with relapsed SCLC
• 	Expanded collaboration agreement to evaluate
combination of I-DXd with MK-6070, an investigational
DLL3 targeting T-cell engager

-- 22 of 29 --

Executing on our broader pipeline
23
Immunology
• 	Received EC approval for
WINREVAIR which has
potential to transform the
treatment journey for patients
with PAH
• 	Presented 50-week efficacy and
safety data for tulisokibart, a
TL1A inhibitor, from Phase 2
ARTEMIS-UC and APOLLO-CD
studies in ulcerative colitis and
Crohn’s disease at UEG Week
Congress
• 	Results reinforce potential to help
patients achieve long-term
clinical remission
Cardiometabolic 	Ophthalmology
• 	Initiated Phase 2b/3 BRUNELLO
trial for MK-3000, an
investigational tetravalent tri-
specific Wnt antibody, for
treatment of diabetic macular
edema

-- 23 of 29 --

Q&A
Rob Davis
Chairman & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Senior Vice President, Investor Relations

-- 24 of 29 --

Appendix
25

-- 25 of 29 --

Q3 2024 GAAP financial results summary
26
Q3 2024 	Q3 2023 	Change 	Change Ex-FX
Sales 	$16.7 	$16.0 	+4% 	+7%
Operating Expenses 	$8.6 	$5.8 	+47% 	+49%
Tax Rate 	22.7% 	15.5% 	+7.2pts 	N/A
GAAP EPS1 $1.24 	$1.86 	-33% 	-30%
$ in billions, EPS amounts
1. 3Q24 GAAP results include a net charge of $0.79 per share for the EyeBio (including milestone), Curon and Daiichi Sankyo transactions

-- 26 of 29 --

$11.7
$3.4
$7.7
$10.1
$1.2
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$ 20B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$11B in the U.S.
Billions
Over the past 12 months
Capital investments
2024 to 2028
Commitment to the dividend
27
Well-positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
Order of priority
1. 	Reflects R&D excluding Business Development
2. 	Includes BD payments reflected in operating cash flow
3. 	Previous values presented at 2Q24 earnings corrected by the company
2
1
E

-- 27 of 29 --

Driving value for patients and shareholders by progressing our pipeline
• 	In the U.S., the FDA approved:
o KEYTRUDA in combination with pemetrexed and platinum chemotherapy for the
first-line treatment of adult patients with unresectable advanced or metastatic
malignant pleural mesothelioma based on IND.227/KN-483
• 	In the EU, the EC approved:
o KEYTRUDA in combination with carboplatin and paclitaxel followed by KEYTRUDA
as a single agent, for the first-line treatment of adult patients with primary
advanced or recurrent endometrial carcinoma who are candidates for systemic
therapy based on NRG-GY018/KN-868
o KEYTRUDA in combination with chemoradiotherapy for the treatment of FIGO
2014 stage III-IVA locally advanced cervical cancer in adults who have not received
prior definitive therapy based on KN-A18
o KEYTRUDA in combination with Padcev for the first-line treatment of adult
patients with unresectable or metastatic urothelial carcinoma based on KN-
A39/EV-302 1
o WINREVAIR in combination with other PAH therapies for the treatment of PAH in
adult patients with WHO FC II to III to increase exercise capacity based on STELLAR
• 	In Japan, the MHLW approved:
o KEYTRUDA in combination with chemotherapy as a neoadjuvant treatment, then
continued as monotherapy as an adjuvant treatment, for patients with NSCLC
based on KN-671
o KEYTRUDA in combination with Padcev for the first-line treatment of patients with
radically unresectable urothelial carcinoma based on KN-A39/EV-302 1
o KEYTRUDA monotherapy in patients with radically unresectable urothelial
carcinoma who are not eligible for any platinum-containing chemotherapy based on
KN-052
30	1. Trial conducted in collaboration with Seagen (now Pfizer) and Astellas 2. In collaboration with Daiichi Sankyo 3. In collaboration with Kelun-Biotech 4. In collaboration with Orion
5. In collaboration with Moderna 6. In partnership with Gilead 7. On FDA partial clinical hold for higher doses than those used in current clinical trials
Announced:
• 	Phase 3 KN-689 trial evaluating KEYTRUDA met its primary endpoint of event-free
survival as perioperative treatment regimen in patients with resected, LA-HNSCC
• 	Phase 3 HERTHENA-Lung02 trial evaluating patritumab deruxtecan (HER3 ADC)2 met
its primary endpoint and demonstrated statistically significant improvement in
progression-free survival in patients with locally advanced or metastatic EGFR-
mutated NSCLC
Presented data from:
• 	Diverse vaccines and infectious disease portfolio at IDWeek, including positive results
from the Phase 2b/3 study evaluating clesrovimab, data from the Phase 3 STRIDE-8
trial evaluating CAPVAXIVE in adults 18-64 years of age at increased risk of
pneumococcal disease, and data from the Phase 2 study evaluating a once-weekly oral
combination regimen of islatravir and lenacapavir for treatment of people with HIV-1
infection
• 	Phase 2 studies evaluating tulisokibart, an investigational humanized monoclonal
antibody directed to TL1A, in ulcerative colitis and Crohn’s disease at UEG Week
• 	Broad oncology portfolio at ESMO, including for KEYTRUDA, WELIREG, Lenvima,
Lynparza, patritumab deruxtecan (HER3 ADC)2, ifinatamab deruxtecan (B7-H3 ADC)2,
sacituzumab tirumotecan (TROP2 ADC)3, and opevsostat (CYP11A1 inhibitor)4
• 	Phase 2 IDeate-Lung01 study at the World Conference on Lung Cancer showing
ifinatamab deruxtecan (B7-H3 ADC)2 in SCLC
Initiated Phase 3 trials evaluating:
• 	V9405, ifinatamab deruxtecan (B7-H3 ADC)2, bomedemstat (LSD1 inhibitor),
zilovertamab vedotin (ROR1 ADC), MK-3000 (Wnt agonist), and the fixed-dose
combination of islatravir and lenacapavir (HIV1) 6,7
Key data & clinical advancements since the last earnings call:	Key regulatory milestones since the last earnings call:

-- 28 of 29 --

Broad and innovative pipeline to address significant unmet medical needs
Phase 2 	Phase 3 	Under regulatory review
V181
Dengue Virus
Vaccines
Infectious disease
MK-8527
HIV-1 Pre-Exposure Prophylaxis
MK-8591B (islatravir+MK-8507)1
HIV-1 infection
MK-2060
Thrombosis
MK-5475
PH-COPD
MK-6024 (efinopegdutide)
NASH
WINREVAIR (MK-7962)
Pulmonary Hypertension due
to Left Heart Disease
Cardiometabolic
MK-4280A
(favezelimab +
pembrolizumab)
Bladder
CRC
cSCC
Endometrial
Esophageal
Melanoma
RCC
MK-5890 (boserolimab)
Neoplasm Malignant
MK-5909 (raludotatug
deruxtecan)4
Ovarian
WELIREG (MK-6482)
Endometrial
Esophageal
HCC
Prostate
Rare Cancers
MK-2400 (ifinatamab
deruxtecan)4
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
Esophageal
HNSCC
Ovarian
MK-2870 (sacituzumab
tirumotecan)5
Biliary
CRC
Neoplasm Malignant
Pancreatic
KEYTRUDA (MK-3475)
Advanced Solid Tumors
Prostate
MK-4280 (favezelimab)
NSCLC
LYNPARZA
(MK-7339)6
Advanced Solid
Tumors
MK-7684A
(vibostolimab
+pembrolizumab)
Bladder
CRC
Endometrial
Melanoma
Ovarian
Prostate
RCC
V940 7
Bladder
cSCC
RCC
MK-1022 (patritumab
deruxtecan)4
Bladder
Cervical
Endometrial
Esophageal
Gastric
HNSCC
Melanoma
Ovarian
Pancreas
Prostate
MK-1308 (quavonlimab)
NSCLC
MK-1308A
(quavonlimab
+pembrolizumab)
CRC
MK-3475A
(pembrolizumab +
hyaluronidase)
cSCC
Heme
1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials	
3 Available in the US under EUA 4 In collaboration with Daiichi Sankyo 5In collaboration with Kelun-Biotech 6 In collaboration with AstraZeneca	
7In collaboration with Moderna 8 In collaboration with Gilead 9 Developed under an agreement with Ridgeback Bio 10In collaboration with Orion
	11In collaboration with Eisai 12Program is in Phase 2/3 study 13 FDA issued CRL in June 2024
MK-6194
Vitiligo
Immunology
Oncology
Infectious disease
Oncology
MK-1022 (patritumab deruxtecan)4
NSCLC (EU)
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1084
NSCLC
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-2140 (zilovertamab vedotin)
Hematological Malignancies
MK-2400 (ifinatamab deruxtecan)4
SCLC
MK-2870 (sacituzumab tirumotecan)5
Breast
Cervical
Endometrial
Gastric
NSCLC
MK-3543 (bomedemstat)
Myeloproliferative Disorders
KEYTRUDA (MK-3475)
Hepatocellular (EU)
Ovarian
SCLC
MK-3475A (pembrolizumab
+hyaluronidase)
NSCLC
MK-4280A (favezelimab
+pembrolizumab)
Hematological Malignancies
MK-5684 (opevesostat)10
Prostate
LYNPARZA (MK-7339)6
NSCLC
SCLC
LENVIMA (MK-7902)11
Esophageal
Gastric
MK-7684A (vibostolimab
+pembrolizumab)
NSCLC
V940 7
Melanoma
NSCLC
MK-8591A (doravirine+islatravir)2
HIV-1 Infection
MK-8591D (islatravir+lenacapavir)2,8
HIV-1 infection
LAGEVRIO (MK-4482)3,9
COVID-19 antiviral
Immunization
MK-1654 (clesrovimab)
Respiratory Syncytial Virus (RSV)
Cardiometabolic
MK-7240 (tulisokibart)
Ulcerative Colitis
Immunology
MK-0616 (enlicitide decanoate)
Hypercholesterolemia 	As of October 31, 2024
Oncology
KEYTRUDA (MK-3475)
Endometrial Carcinoma (JPN)
Cervical (JPN)
Mesothelioma (EU, JPN)
MK-1022 (patritumab deruxtecan)4, 13
NSCLC (US)
WELIREG (MK-6482)
Advanced RCC (EU, JPN)
Certain VHL tumors (EU, JPN)
Vaccines
CAPVAXIVE (V116)
Pneumococcal conjugate vaccine, adult (EU,
JPN)
MK-3000 12
Diabetic macular edema
Ophthalmology

-- 29 of 29 --